JY
CLYM

Jeff Yass’s Climb Bio CLYM Stock Holding History

Jeff Yass’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$349K Buy
+26,800
New +$277K ﹤0.01% 10717

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jeff Yass's CLYM Position: Q2 2026 in Review

Jeff Yass reduced its Climb Bio (CLYM) stake by 92% in Q2 2026, selling an estimated $3.69M and leaving 30,279 shares worth $395K. The position accounts for ﹤0.01% of the portfolio, ranked #10443.

Jeff Yass first reported a position in CLYM in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.65M in Q1 2026. 108 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Jeff Yass held 30,279 shares of Climb Bio worth $395K as of Q2 2026.
  • Jeff Yass sold 357,124 Climb Bio shares in Q2 2026, an estimated $3.69M.
  • Climb Bio made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10443 holding.
  • Jeff Yass first reported a position in Climb Bio in Q4 2024 and has held it in 7 quarters since.
  • Jeff Yass's Climb Bio position peaked at $2.65M in Q1 2026.
  • 108 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.